Biolargo Stock Price, News & Analysis

BioLargo, Inc. (OTCQB:BLGO) is advancing the commercialization of its innovative wastewater treatment technology, the minimal liquid discharge system, developed for Garratt-Callahan. The company will use a full-scale prototype to treat simulated and actual industrial wastewater, aimed at optimizing performance before sales to Garratt-Callahan customers begin. This technology is designed to reduce wastewater volume and disposal costs, while also enhancing environmental sustainability. BioLargo emphasizes its commitment to sustainable solutions and innovation in wastewater treatment.

BioLargo, Inc. (OTCQB:BLGO) has entered into a manufacturer's representative agreement with ICS Group, focusing on the sale of its innovative water treatment technologies. This partnership marks a significant step in expanding BioLargo's commercial network. ICS Group will promote BioLargo's proprietary solutions, including the Advanced Oxidation System and the Aqueous Electrostatic Concentrator, designed for wastewater treatment and PFAS contamination removal. The deal also includes BioLargo's PFAS Testing Program and CupriDyne Clean odor control product.

BioLargo, Inc. (OTCQB:BLGO) has received a 'go decision' from its partner Ikigai Holdings to expand television advertising for its new pet odor control product, 'POOPH'. The decision follows successful test marketing results, indicating strong potential for the product's commercial success. Ikigai CEO Jane Pak highlighted positive early feedback and plans for an extensive marketing campaign post-Christmas. BioLargo CEO Dennis P. Calvert mentioned the partnership could generate significant revenue, with Ikigai managing product rollout and distribution.

BioLargo, Inc. (OTCQB:BLGO) has filed its Quarterly Report for Q3 2021, revealing a 7% increase in consolidated revenue to $712,000, largely driven by a 73% rise in the engineering division. The company's net loss decreased to $1.3 million, down from $2.1 million the previous year due to reduced interest expenses. Key progress includes successful PFAS treatment tests with prospective clients, completion of a prototype for Garratt-Callahan, and promising pilot results for the AOS technology, solidifying its position for future growth.

BioLargo, Inc. (OTCQB:BLGO) will host an investor webcast on November 17, 2021, at 8:00 AM PST / 11:00 AM EST, to discuss its financial results and recent commercial milestones. The event is public and will include a Q&A session. Investors can access the live stream and replay through the company's website. BioLargo specializes in sustainable environmental technologies, holding numerous patents and executing various projects, while also emphasizing partnerships and innovative solutions to environmental challenges.

BioLargo, Inc. (OTCQB:BLGO) announced a peer-reviewed article confirming the efficacy of its water treatment technology, the Advanced Oxidation System (AOS). Published in ACS ES&T Water, the study reveals that AOS generates highly energetic iodine molecules, enhancing disinfection efficiency. Currently being tested at a municipal wastewater facility, AOS demonstrates superior performance and lower energy consumption compared to traditional methods. The research employed advanced measurement techniques, establishing AOS as a significant advancement in sustainable water treatment technology.

BioLargo, Inc. (BLGO) shared a letter to stockholders on September 30, 2021, outlining strategic partnerships to enhance its market presence. Notably, BioLargo is launching a wastewater treatment product with Garratt-Callahan, aiming to sell 25-35 units within the first year. They also plan to commercially launch their PFAS treatment device, AEC, in early 2022. Additionally, a new consumer product partnership is underway with Ikigai Holdings. Overall, BioLargo is focusing on revenue growth and improving financial health, having significantly reduced debt while pursuing sustainable business solutions.

BioLargo, Inc. (OTCQB:BLGO) will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dennis Calvert will discuss the company's innovative cleantech products, including its new PFAS Testing Program. The presentation is scheduled for September 13 at 7:00 am ET and will be available on demand for 90 days. Investors can register for free to view the presentation. BioLargo focuses on environmental technologies to tackle PFAS contamination and enhance water treatment solutions.

BioLargo, Inc. (OTCQB:BLGO) has launched a new PFAS Testing Program to help customers identify PFAS contamination in their water. This program addresses the growing regulatory challenges regarding PFAS, a group of harmful chemicals found in drinking water. The testing provides accurate results, enabling the company to recommend appropriate treatment solutions. BioLargo's Aqueous Electrostatic Concentrator (AEC) offers a sustainable method for PFAS removal, generating significantly less waste than conventional methods. This initiative aims to support municipalities facing PFAS-related water well closures.